On March 12, the California Supreme Court denied review of a $407 million judgment, which included approximately $360 million in lost-profit damages, arising from Swiss drugmaker Actelion Ltd.’s acquisition of California biotech startup CoTherix, Inc.
Some observers have predicted that the published appellate court opinion affirming the judgment will cause a wave in lost-profit litigation, push pharmaceutical firms out California, and discourage companies from participating in mergers and acquisitions, ultimately hampering California’s notorious start-up culture. In this seminar, the Asahi trial and appellate team will address these concerns and cover the following three topics of interest arising from the litigation:
first cup of coffee
briefing on patent and IP litigation matters
April 23, 2014
2 Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
8:30–9:00 am | breakfast and registration
9:00–10:30 am | program
Rollin B. Chippey, II
Benjamin P. Smith
Christopher J. Banks
registration or questions?
Call 415.442.1680 or email email@example.com.
This program is currently pending approval in the following state/jurisdiction: CA